Navigation Links
Cepheid Reports Fourth Quarter And Full Year 2012 Results
Date:1/24/2013

p>13,44610,298Amortization of intangible assets 

4,9656,523Amortization of terminated patent license and impairment of acquired intangible assets

1,3995,372Stock-based compensation related to employees and consulting services rendered

24,49619,768Changes in operating assets and liabilities:Accounts receivable 

(6,443)(7,830)Inventory 

(5,105)(23,982)Prepaid expenses and other current assets 

(2,714)(237)Other non-current assets

(172)(122)Accounts payable and other current liabilities 

(5,740)11,365Accrued compensation 

(1,736)5,334Deferred revenue 

575(2,084)Net cash provided by operating activities 

2,92827,032Cash flows from investing activities:Capital expenditures 

(23,150)(18,922)Cash paid for intangible asset

(2,140)-Payments for technology licenses 

-(1,655)Cost of acquisitions, net

(24,021)(296)Net cash used in investing activities 

(49,311)(20,873)Cash flows from financing activities:Net proceeds from the issuance of common shares and exercise of stock options

27,07935,857Proceeds from notes payable

156-Principal payment of notes payable

(72)(6,669)Net cash provided by financing activities 

27,16329,188Effect of exchange rate change on cash

(9)123Net increase (decrease) in cash and cash equivalents 

(19,229)35,470Cash and cash equivalents at beginning of period 

115,00879,538Cash and cash equivalents at end of period

$   95,779$  115,008 CEPHEID  

RECONCILIATION OF GAAP TO NON-GAAP MEASURES (UNAUDITED)(in thousands, except per share data)Three Months Ended
December 31,Years Ended
December 31,2012201120122011Cost of product sales$ 42,896$ 38,632$ 153,365$ 122,840  Stock compensation expense(808)(443)(3,037)(1,684)  Impairment of i
'/>"/>

SOURCE Cepheid
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Announces Executive Vice President Emerging Markets
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
6. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
7. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
8. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
9. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
10. Luminex Corporation Reports First Quarter 2012 Results
11. Hospira Reports First-Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... CHAPEL HILL, N.C. , Feb. 27, 2015 /PRNewswire/ ... the challenge of managing multiple products for the same ... especially for those that want to prevent one of ... of another.  According to recent research by ... promoted their products as independent brands rather than together ...
(Date:2/27/2015)... SHANGHAI , Feb. 27, 2015 WuXi ... capability and technology platform company serving the pharmaceutical, biotechnology, ... China and the United States ... breakthrough therapy designation from the U.S. FDA for ibalizumab ... therapy if it is intended, alone or in combination ...
(Date:2/27/2015)...  Pharmacyclics, Inc. (NASDAQ: PCYC ) ... in the Proceedings of the National Academy ... when ibrutinib (IMBRUVICA ® ) was combined with ... tumor growth was enhanced suggesting a greater response ... and solid tumors with the combination. IMBRUVICA is ...
Breaking Medicine Technology:New Report Details How to Expand a Pharmaceutical Product Portfolio without Cannibalizing an Established Brand 2WuXi Congratulates TaiMed Biologics on Receiving Breakthrough Therapy Designation from U.S. FDA 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9
... Henry Schein, Inc. (NASDAQ: HSIC ), the ... practitioners, announced today that Ferdinand Jahnel, Vice President ... 9th Annual Best Ideas Conference 2011. The conference is taking ... Henry Schein,s presentation is scheduled to begin ...
... WOODLANDS, Texas, Sept. 13, 2011 Lexicon Pharmaceuticals, ... company focused on discovering breakthrough treatments for human disease, ... and mechanistic study of LX4211, a dual inhibitor of ... SGLT2).  The favorable safety profile and effects on multiple ...
Cached Medicine Technology:Henry Schein to Present at the CL King 9th Annual Best Ideas Conference 2011 2LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects 2LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects 3LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects 4
(Date:3/1/2015)... March 01, 2015 Women’s Excellence ... Overactive Bladder (OAB) symptoms, such as a strong need to ... type of medication (anticholinergic) does not work well enough or ... that takes another approach to targeting the source of OAB, ... the nerves and bladder muscle, blocking the signals that trigger ...
(Date:3/1/2015)... March 01, 2015 Ticket Down is a ... Chicago at Soldier Field. Deadheads have been anxiously ... January. , Grateful Dead was formed 50 years ago back ... together as one until the untimely death of Jerry Garcia ... different genres including blues, reggae, rock, bluegrass, folk, space rock ...
(Date:3/1/2015)... (PRWEB) March 01, 2015 Theme and ... new transition pack for Final Cut Pro ... accordion style transitions to any FCPX editors project.” Said ... our users the tools needed to easily drag and ... The user gets many different controls over the parameters ...
(Date:2/28/2015)... In a recent episode of SCI ... Change Athlete Development Services and Consultancy talks with ... athlete development and player engagement during and after their ... athletes face and how off-field activities are a critical ... involved in athlete development issues while in graduate school ...
(Date:2/28/2015)... Morristown, NJ (PRWEB) February 28, 2015 ... Month—is a good time to remind ourselves and ... be ignored, say Atlantic NeuroSurgical Specialists (ANS). , ... (TBI), which account for 75% of TBIs. There ... word concussion may sound benign, but it is ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2Health News:Grateful Dead Tickets at Soldier Field in Chicago: Ticket Down Slashes Grateful Dead Ticket Prices in Chicago at Soldier Field for 4th of July Weekend Celebration 2Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3
... moderate consumption of alcohol may cut the rate of ... 225 men after they had undergone a percutaneous transluminal ... with a stent. Less traumatic than bypass surgery, a ... in renarrowing of the artery, usually within four months. ...
... in Britain has increased by more than 50 percent over ... as exposure to radiation, benzene, and environmental pollutants, are thought ... ,Research conducted shows that the low incidence of leukemia in ... the spice turmeric, which is widely used in Asian cooking. ...
... cancer is the leading cause of cancer death among men ... // have double the risk of developing lung cancer from ... nearly 3,000 men and women ages 40 and older with ... as age, gender and number of years smoking -- impacted ...
... associated with an increased risk of heart disease and breast ... whether or not to use the treatment. ,Doctors ... around 50 years old who are first facing menopause. These ... hot flashes and night sweats and for them, the treatment ...
... it’s in a more advanced stage is key to survival ... study.// While a CT scan can detect early lung cancer, ... A new study conducted by researchers who wanted to look ... ,The research was part of the Early Lung ...
... focused on depression in elderly people living in the community ... // depression and its symptoms have been shown to accelerate ... 250 participants in a community health program. At the start ... then did so again at 18 months. At the beginning, ...
Cached Medicine News:
Microforceps : Eckardt End & Side Gripping Forceps...
Blunt tipped forceps wlth a small grasping platform on each tip. For grasping fine membranes or grasping membranes adherent to the retinal surface....
Microforceps: Spaid Pic Forceps...
Blunt tipped forceps with small, slightly pointed grasping platforms on each tip. For general purpose (fine) membrane grasping and grasping membranes adherent to the retlnal surface....
Medicine Products: